AU2020904323A0 - Use of sugar cane extracts in the treatment or prevention of microbial infections and dysbiosis - Google Patents

Use of sugar cane extracts in the treatment or prevention of microbial infections and dysbiosis

Info

Publication number
AU2020904323A0
AU2020904323A0 AU2020904323A AU2020904323A AU2020904323A0 AU 2020904323 A0 AU2020904323 A0 AU 2020904323A0 AU 2020904323 A AU2020904323 A AU 2020904323A AU 2020904323 A AU2020904323 A AU 2020904323A AU 2020904323 A0 AU2020904323 A0 AU 2020904323A0
Authority
AU
Australia
Prior art keywords
dysbiosis
prevention
treatment
sugar cane
microbial infections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020904323A
Inventor
Matthew FLAVEL
Barry Kitchen
Shane MITCHELL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Product Makers Australia Pty Ltd
Original Assignee
Product Makers Australia Pty Ltd
Filing date
Publication date
Application filed by Product Makers Australia Pty Ltd filed Critical Product Makers Australia Pty Ltd
Publication of AU2020904323A0 publication Critical patent/AU2020904323A0/en
Priority to CN202180078823.4A priority Critical patent/CN116847862A/en
Priority to AU2021384768A priority patent/AU2021384768B2/en
Priority to PCT/AU2021/051395 priority patent/WO2022104438A1/en
Priority to US18/253,873 priority patent/US20230414695A1/en
Priority to JP2023530947A priority patent/JP2023550768A/en
Priority to EP21893156.6A priority patent/EP4247400A4/en
Priority to CA3199002A priority patent/CA3199002A1/en
Priority to AU2024204161A priority patent/AU2024204161B2/en
Pending legal-status Critical Current

Links

AU2020904323A 2020-11-23 2020-11-23 Use of sugar cane extracts in the treatment or prevention of microbial infections and dysbiosis Pending AU2020904323A0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CN202180078823.4A CN116847862A (en) 2020-11-23 2021-11-23 Use of sugarcane extract for treating or preventing microbial infection and dysbiosis
AU2021384768A AU2021384768B2 (en) 2020-11-23 2021-11-23 Use of sugar cane extracts in the treatment or prevention of microbial infections and dysbiosis
PCT/AU2021/051395 WO2022104438A1 (en) 2020-11-23 2021-11-23 Use of sugar cane extracts in the treatment or prevention of microbial infections and dysbiosis
US18/253,873 US20230414695A1 (en) 2020-11-23 2021-11-23 Use of sugar cane extracts in the treatment or prevention of microbial infections and dysbiosis
JP2023530947A JP2023550768A (en) 2020-11-23 2021-11-23 Use of sugarcane-derived extracts to treat or prevent microbial infections and dysbiosis
EP21893156.6A EP4247400A4 (en) 2020-11-23 2021-11-23 Use of sugar cane extracts in the treatment or prevention of microbial infections and dysbiosis
CA3199002A CA3199002A1 (en) 2020-11-23 2021-11-23 Use of sugar cane extracts in the treatment or prevention of microbial infections and dysbiosis
AU2024204161A AU2024204161B2 (en) 2020-11-23 2024-06-19 Use of sugar cane extracts in the treatment or prevention of microbial infections and dysbiosis

Publications (1)

Publication Number Publication Date
AU2020904323A0 true AU2020904323A0 (en) 2020-12-10

Family

ID=

Similar Documents

Publication Publication Date Title
EP3684353A4 (en) Topical formulations of cannabinoids and use thereof in the treatment of pain
WO2005004810A3 (en) Arylsulfonamide derivatives
WO2021234160A3 (en) Ace2-fc fusion proteins and uses thereof
EP3915985A4 (en) Pyrrolopyridine derivative and use thereof in prevention and treatment of protein kinase-related disease
EP4247400A4 (en) Use of sugar cane extracts in the treatment or prevention of microbial infections and dysbiosis
EP4094763A4 (en) Use of compound in prevention and/or treatment of pathogen infection in animals
WO2022090469A3 (en) Ace2 fusion proteins and uses thereof
EP4153168A4 (en) Use of terpenoids in the treatment or prevention of fibrotic diseases
WO2021004958A3 (en) Compositions comprising bacterial strains
WO2005018542A3 (en) Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
EP3913002A4 (en) Application of ecm1 in prevention and/or treatment of liver fibrosis-related diseases
AU2020904323A0 (en) Use of sugar cane extracts in the treatment or prevention of microbial infections and dysbiosis
EP3814326A4 (en) Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases
EP3790866A4 (en) Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases
EP4126855C0 (en) Compounds and their use in the treatment of bacterial infections
EP4003355A4 (en) Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases
IL273297A (en) Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections
EP3785535A4 (en) Composition for use in the hygiene, prevention and/or treatment of common infections in fish farming
EP3983535A4 (en) Stabilized mutants of quorum quenching lactonase and use thereof in treatment of pathogens
EP4017496A4 (en) Formulations for use in the prevention and/or treatment of peripheral neuropathy and its associated diseases
EP4088735A4 (en) Application of cst1 in prevention and/or treatment of liver immune dysregulation diseases
EP4114423A4 (en) Compositions and methods for the treatment of intracellular bacterial infections
EP4003997A4 (en) Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases
EP4003987A4 (en) Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases
EP4112637A4 (en) Polypeptide compound and application thereof in prevention or treatment of diabetes or diabetes complication